Schonfeld Strategic Advisors LLC Purchases 467,738 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Schonfeld Strategic Advisors LLC raised its position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 28.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,113,272 shares of the company's stock after acquiring an additional 467,738 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 2.33% of Caribou Biosciences worth $3,360,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Centric Wealth Management bought a new stake in shares of Caribou Biosciences in the 4th quarter valued at approximately $27,000. Russell Investments Group Ltd. increased its position in Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock valued at $38,000 after acquiring an additional 21,416 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after acquiring an additional 9,148 shares during the period. Diametric Capital LP bought a new stake in shares of Caribou Biosciences in the 4th quarter worth about $42,000. Finally, US Bancorp DE boosted its stake in shares of Caribou Biosciences by 3,524.2% during the 4th quarter. US Bancorp DE now owns 27,218 shares of the company's stock worth $43,000 after purchasing an additional 26,467 shares during the period. 77.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CRBU. HC Wainwright reissued a "buy" rating and issued a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a research note on Monday, April 28th. Bank of America dropped their price objective on Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $9.33.

Caribou Biosciences Stock Performance

CRBU traded up $0.01 during trading on Wednesday, hitting $0.76. 453,361 shares of the stock were exchanged, compared to its average volume of 1,544,306. Caribou Biosciences, Inc. has a 1 year low of $0.66 and a 1 year high of $3.92. The firm has a market cap of $70.68 million, a price-to-earnings ratio of -0.46 and a beta of 2.36. The firm has a 50 day simple moving average of $0.91 and a 200 day simple moving average of $1.48.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.08 million for the quarter, compared to analysts' expectations of $2.11 million. As a group, equities analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.